Form 4 for AVTX Avalo Therapeutics, Inc.
Accepted 2026-05-07 16:16:49 ET · period of report 2026-05-06 · accession 0001810417-26-000010 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-05-07 16:16 | 2026-05-06 | AVTX | Sullivan Christopher Ryan | CFO | M - OptEx | $8.04 | +47.0K | 47.4K | +11,111% | +$377.9K |
| DMT | 2026-05-07 16:16 | 2026-05-06 | AVTX | Sullivan Christopher Ryan | CFO | S - Sale+OE | $20.19 | -47.0K | 423 | -99% | -$948.7K |
| DT | 2026-05-07 16:16 | 2026-05-06 | AVTX | Sullivan Christopher Ryan | CFO | M - OptEx | $0.00 | -47.0K | 116.0K | -29% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-06 | M | A | 47,000 | $8.04 | 47,423 | D | — | — | (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. |
| 2 | Common | Common Stock | 2026-05-06 | S | D | 13,834 | $18.55 | 33,589 | D | — | — | (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. (F2) The reported securities were sold in multiple transactions at prices ranging from $17.95 to $18.90. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. |
| 3 | Common | Common Stock | 2026-05-06 | S | D | 12,347 | $19.28 | 21,242 | D | — | — | (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. (F3) The reported securities were sold in multiple transactions at prices ranging from $19.02 to $19.91. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. |
| 4 | Common | Common Stock | 2026-05-06 | S | D | 2,700 | $20.76 | 18,542 | D | — | — | (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. (F4) The reported securities were sold in multiple transactions at prices ranging from $20.04 to $20.81. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. |
| 5 | Common | Common Stock | 2026-05-06 | S | D | 9,219 | $21.37 | 9,323 | D | — | — | (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. (F5) The reported securities were sold in multiple transactions at prices ranging from $21.10 to $21.90. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. |
| 6 | Common | Common Stock | 2026-05-06 | S | D | 8,900 | $22.57 | 423 | D | — | — | (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. (F6) The reported securities were sold in multiple transactions at prices ranging from $22.26 to $22.88. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. |
| 7 | Derivative | Stock Option (Right to Buy) | 2026-05-06 | M | D | 47,000 | $0.00 | 116,000 | D | $8.04 · — to 2035-01-28 | 47,000 Common Stock | (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. (F7) The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date. |